Cidara Therapeutics Inc. (CDTX)
Company Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States.
The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19.
The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014.
Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
| Country | United States |
| IPO Date | Apr 15, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 38 |
| CEO | Dr. Jeffrey L. Stein Ph.D. |
Contact Details
Address: 6310 Nancy Ridge Drive San Diego, California United States | |
| Website | https://www.cidara.com |
Stock Details
| Ticker Symbol | CDTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001610618 |
| CUSIP Number | 171757107 |
| ISIN Number | US1717571079 |
| Employer ID | 46-1537286 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeffrey L. Stein Ph.D. | President, Chief Executive Officer & Executive Director |
| Frank L. Karbe M.B.A. | Chief Financial Officer |
| Shane M. Ward J.D. | Chief Operating Officer & Corporate Secretary |
| Allison Lewis CCP, SPHR | Senior Vice President of People & Culture |
| Dr. Kevin M. Forrest Ph.D. | Founder & Chief Strategy Officer |
| Dr. Leslie Tari Ph.D. | Chief Scientific Officer |
| Dr. Nicole Davarpanah J.D., M.D. | Interim Chief Medical Officer and Senior Vice President of Translational Research & Development |
| Dr. Preetam Shah M.B.A., Ph.D. | Principal Accounting Officer |
| Jim Beitel M.B.A. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 13, 2025 | 4 | Filing |
| Mar 13, 2025 | 4 | Filing |
| Mar 06, 2025 | S-8 | Filing |
| Mar 06, 2025 | 8-K | Current Report |
| Mar 06, 2025 | 10-K | Annual Report |
| Feb 26, 2025 | 4 | Filing |
| Feb 26, 2025 | 3 | Filing |
| Feb 18, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 07, 2025 | 4 | Filing |